687 related articles for article (PubMed ID: 19241193)
1. AFP promoter enhancer increased specific expression of the human sodium iodide symporter (hNIS) for targeted radioiodine therapy of hepatocellular carcinoma.
Ma XJ; Huang R; Kuang AR
Cancer Invest; 2009 Jul; 27(6):673-81. PubMed ID: 19241193
[TBL] [Abstract][Full Text] [Related]
2. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma.
Willhauck MJ; Sharif Samani BR; Klutz K; Cengic N; Wolf I; Mohr L; Geissler M; Senekowitsch-Schmidtke R; Göke B; Morris JC; Spitzweg C
Gene Ther; 2008 Feb; 15(3):214-23. PubMed ID: 17989705
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine therapy of hepatoma using targeted transfer of the human sodium/iodide symporter gene.
Chen L; Altmann A; Mier W; Eskerski H; Leotta K; Guo L; Zhu R; Haberkorn U
J Nucl Med; 2006 May; 47(5):854-62. PubMed ID: 16644756
[TBL] [Abstract][Full Text] [Related]
4. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer.
Kakinuma H; Bergert ER; Spitzweg C; Cheville JC; Lieber MM; Morris JC
Cancer Res; 2003 Nov; 63(22):7840-4. PubMed ID: 14633711
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene.
Kanai F; Shiratori Y; Yoshida Y; Wakimoto H; Hamada H; Kanegae Y; Saito I; Nakabayashi H; Tamaoki T; Tanaka T; Lan KH; Kato N; Shiina S; Omata M
Hepatology; 1996 Jun; 23(6):1359-68. PubMed ID: 8675152
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter.
Ido A; Uto H; Moriuchi A; Nagata K; Onaga Y; Onaga M; Hori T; Hirono S; Hayashi K; Tamaoki T; Tsubouchi H
Cancer Res; 2001 Apr; 61(7):3016-21. PubMed ID: 11306481
[TBL] [Abstract][Full Text] [Related]
7. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter.
Spitzweg C; O'Connor MK; Bergert ER; Tindall DJ; Young CY; Morris JC
Cancer Res; 2000 Nov; 60(22):6526-30. PubMed ID: 11103823
[TBL] [Abstract][Full Text] [Related]
8. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter.
Dwyer RM; Bergert ER; O'connor MK; Gendler SJ; Morris JC
Clin Cancer Res; 2005 Feb; 11(4):1483-9. PubMed ID: 15746050
[TBL] [Abstract][Full Text] [Related]
9. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer.
Scholz IV; Cengic N; Baker CH; Harrington KJ; Maletz K; Bergert ER; Vile R; Göke B; Morris JC; Spitzweg C
Gene Ther; 2005 Feb; 12(3):272-80. PubMed ID: 15510175
[TBL] [Abstract][Full Text] [Related]
10. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy.
Boland A; Ricard M; Opolon P; Bidart JM; Yeh P; Filetti S; Schlumberger M; Perricaudet M
Cancer Res; 2000 Jul; 60(13):3484-92. PubMed ID: 10910060
[TBL] [Abstract][Full Text] [Related]
12. Specific activation of sodium iodide symporter gene in hepatoma using alpha-fetoprotein promoter combined with hepatitis B virus enhancer (EIIAPA).
Liu RS; Hsieh YJ; Ke CC; Chen FD; Hwu L; Wang FH; Hwang JJ; Chi CW; Lee CH; Yeh SH
Anticancer Res; 2009 Jan; 29(1):211-21. PubMed ID: 19331152
[TBL] [Abstract][Full Text] [Related]
13. Cotransfected sodium iodide symporter and human tyroperoxidase genes following human telomerase reverse transcriptase promoter for targeted radioiodine therapy of malignant glioma cells.
Li W; Tan J; Wang P; Wu P
Cancer Biother Radiopharm; 2011 Aug; 26(4):443-51. PubMed ID: 21797672
[TBL] [Abstract][Full Text] [Related]
14. Retrovirus-mediated gene therapy for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by human alpha-fetoprotein enhancer directly linked to its promoter.
Mawatari F; Tsuruta S; Ido A; Ueki T; Nakao K; Kato Y; Tamaoki T; Ishii N; Nakata K
Cancer Gene Ther; 1998; 5(5):301-6. PubMed ID: 9824049
[TBL] [Abstract][Full Text] [Related]
15. Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector.
Guan M; Rodriguez-Madoz JR; Alzuguren P; Gomar C; Kramer MG; Kochanek S; Prieto J; Smerdou C; Qian C
Cancer Res; 2006 Feb; 66(3):1620-9. PubMed ID: 16452221
[TBL] [Abstract][Full Text] [Related]
16. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy.
Mitrofanova E; Unfer R; Vahanian N; Link C
Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells.
Kim KI; Kang JH; Chung JK; Lee YJ; Jeong JM; Lee DS; Lee MC
J Nucl Med; 2007 Sep; 48(9):1553-61. PubMed ID: 17704247
[TBL] [Abstract][Full Text] [Related]
18. Retrovirus-mediated gene therapy for hepatocellular carcinoma with reversely oriented therapeutic gene expression regulated by alpha-fetoprotein enhancer/promoter.
Ishikawa H; Nakata K; Mawatari F; Ueki T; Tsuruta S; Ido A; Nakao K; Kato Y; Ishii N; Eguchi K
Biochem Biophys Res Commun; 2001 Oct; 287(4):1034-40. PubMed ID: 11573968
[TBL] [Abstract][Full Text] [Related]
19. Iodide kinetics and dosimetry in vivo after transfer of the human sodium iodide symporter gene in rat thyroid carcinoma cells.
Haberkorn U; Beuter P; Kübler W; Eskerski H; Eisenhut M; Kinscherf R; Zitzmann S; Strauss LG; Dimitrakopoulou-Strauss A; Altmann A
J Nucl Med; 2004 May; 45(5):827-33. PubMed ID: 15136633
[TBL] [Abstract][Full Text] [Related]
20. Tumor-targeted gene therapy using Adv-AFP-HRPC/IAA prodrug system suppresses growth of hepatoma xenografted in mice.
Dai M; Liu J; Chen DE; Rao Y; Tang ZJ; Ho WZ; Dong CY
Cancer Gene Ther; 2012 Feb; 19(2):77-83. PubMed ID: 21959967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
